1 Beaten-Down AI Stock to Buy and 1 to Avoid

Alphabet is down ~13% YTD but is executing AI across search, cloud services and Gemini subscriptions and is characterized as a wide-moat company with multiple growth avenues despite heavy AI-related investments. Recursion Pharmaceuticals has no marketed products and no phase‑3 candidates, remains consistently unprofitable, and is labeled high-risk despite its AI-driven drug-discovery platform. The piece is an analyst view (Motley Fool) highlighting Alphabet as a buy-and-hold AI leader while recommending caution or avoidance for Recursion for investors with average risk tolerance.

Analysis

Alphabet’s AI investments create asymmetric optionality: successful productized features can re-price user engagement and ad yield within 12–24 months, while failure mainly forces a return to cost discipline rather than existential impairment. Second-order beneficiaries include GPU/HBM suppliers and colo/power vendors as Alphabet internalizes larger model training workloads — that raises industry-wide demand for high-bandwidth memory and datacenter power capacity, tightening supply chains for NVDA/INTC suppliers over the next 4–8 quarters.

Recursion illustrates the classic platform vs. product dichotomy: an AI-driven discovery platform promises long-term scaling benefits but faces binary, idiosyncratic clinical risk where a single failed pivotal readout can erase multi-year implied option value. That makes RXRX’s path to derisking heavily calendar-dependent — expect headline-driven 30–70% moves around trial readouts and fundraising windows within 6–18 months rather than steady value accretion.

From a positioning perspective, alpha is available by separating durable platform optionality (Alphabet) from high-variance biotech R&D bets (Recursion). Key near-term risks that would reverse the current tilt include a regulatory shock (accelerated antitrust action tying product launches for 3–6 quarters), a rapid climb in model compute costs that pushes AI margin breakeven beyond 24 months, or an RXRX positive clinical surprise that materially re-rates its narrative overnight.

Key Decisions for Investors

• Long GOOGL (core position) — size 3–5% NAV, horizon 12–24 months. Use a 12–18 month call spread (buy 2027 Jan LEAPs, sell nearer-dated calls) to finance carry; reward = capture mid-teens to 30%+ rerating if AI monetization accelerates, risk = ~15–25% drawdown if ad cyclicality and compute costs compress margins.
• Pair trade: long GOOGL / short RXRX — long:short notional 3:1 to reflect vol difference, horizon 6–18 months. This isolates platform AI upside vs. clinical execution risk; if Alphabet progresses product monetization while Recursion hits clinical fundraising/negative readouts, expect asymmetric payoff where pair appreciates >25% with limited net capital outlay.
• Buy RXRX downside protection (puts) rather than naked short exposure — buy 6–12 month puts sized to 0.5–1% NAV as hedge/short exposure. Rationale: preserves ability to capture sudden negative clinical/regulatory moves (30–70% downside scenarios) while avoiding unlimited short risk on rare positive binary outcomes.
• Tactical conditional trade on NVDA: accumulate on >10% pullback (or buy 6–12 month OTM calls) to express incremental datacenter/GPU demand from hyperscalers like Alphabet over next 4–8 quarters. Risk: valuation already rich; hedge with a small short-dated put sale or reduce position if enterprise capex softens.